#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
“We’re seeing seniors self-treat with unregulated CBD products for pain, anxiety, and sleep without any clinical oversight, which is problematic not because CBD is inherently dangerous, but because we have no standardized dosing, no quality control, and no systematic way to track drug interactions with their existing medications. Until we have FDA-regulated CBD products and Medicare coverage for legitimate indications studied in rigorous trials, my patients deserve better than being left to navigate an unmonitored marketplace on their own.”
💊 The regulatory landscape surrounding cannabidiol (CBD) products available to Medicare beneficiaries remains fragmented, with limited FDA oversight and significant variation in product quality, labeling accuracy, and clinical evidence supporting their use. Older adults are increasingly purchasing CBD products for pain, anxiety, and sleep, yet clinicians face substantial uncertainty about appropriate dosing, drug interactions (particularly with common medications metabolized through CYP3A4), and the actual therapeutic efficacy in this population. The gap between consumer enthusiasm and rigorous clinical trial data in seniors is substantial, and the heterogeneity of available products means patients may receive inconsistent or mislabeled doses. Healthcare providers should routinely ask Medicare patients about CBD use during medication reviews, document these purchases in the medical record, and counsel patients about the lack of definitive evidence in older adults while monitoring for potential interactions with their existing medications. Until higher-quality evidence emerges specifically in geriatric populations, clin
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: